Error loading player: No playable sources found
2530
Novel Observations in IBD
Date
May 18, 2024
This product is not available for individual purchase, but it is available as part of the following products:
Full DDW 2024 On Demand Program available now!
SOCIETY: AGA
Presentations:
| MONITORING IBD BY INTESTINAL ULTRASOUND DECREASES TIME TO TREATMENT CHANGE AND TIME TO REMISSION IN COMPARISON TO CONVENTIONAL MANAGEMENT: ANALYSIS OF PATIENTS WITH IBD ON MULTIPLE IBD THERAPIES |
| COST-EFFECTIVENESS OF A BIOMARKER MONITORING STRATEGY COMPARED TO ENDOSCOPIC MONITORING IN LOW-RISK POSTOPERATIVE CROHN’S DISEASE. |
| ONE-YEAR COMPARATIVE EFFECTIVENESS OF UPADACITINIB VERSUS TOFACITINIB FOR ULCERATIVE COLITIS: A MULTICENTER COHORT STUDY |
| MULTIMODAL PREHABILITATION IS ASSOCIATED WITH IMPROVED SURGICAL OUTCOMES IN IBD |
| NATURAL HISTORY OF PRESUMED ISOLATED CROHN'S DISEASE PERIANAL FISTULA |
| BOWEL HABITS AND QUALITY OF LIFE IN ULCERATIVE COLITIS PATIENTS UNDERGOING J POUCH CONSTRUCTION: A RETROSPECTIVE ANALYSIS AT 6- AND 12-MONTHS POST-FUNCTIONALIZATION |
Moderators
Vanderbilt University Medical Center
Mayo Foundation for Medical Education and Research
Tracks
Related Products
Uncontrolled Therapeutic Observations in IBD
SOCIETY: AGA In this session, several clinically relevant presentations will put the attendee at the cutting edge of research and clinical care, with regard to stem cells for perinal fistulas, biologic de-escalation, subcutaneous biologics, and use of small molecules in microscopic colitis
Role of the Environment in IBD
SOCIETY: AGA As our scientific tools improve, so does our ability to link the environment with different aspects of IBD…
IBD Controlled Trials I
SOCIETY: AGA
IBD Controlled Trials II
SOCIETY: AGA This session is the second session of the ever-popular and clinically impactful clinical trials sessions in IBD. Insights into novel agents including obefazimod, VTX002. MH002, risankizumab, and mirikizumab will be presented…
